|
Malignant tumor of colon
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
WiNTRLINC1 was not significantly associated with prognostic factors in colon cancer and other lncRNAs, while the WiNTRLINC1/ASCL2/c-Myc signatures were unique to young-onset colon cancer with differentiated histology.
|
31549316 |
2019 |
|
Malignant tumor of colon
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The transcription factor Ascl2 (Wnt target gene) is fate decider of intestinal cryptic stem cells and colon cancer stem cells.
|
29886802 |
2018 |
|
Malignant tumor of colon
|
0.350 |
Biomarker
|
disease |
BEFREE |
The intestinal stem cell regulating gene ASCL2 is required for L1-mediated colon cancer progression.
|
29551399 |
2018 |
|
Malignant tumor of colon
|
0.350 |
Biomarker
|
disease |
BEFREE |
Ascl2 activation by YAP1/KLF5 ensures the self-renewability of colon cancer progenitor cells.
|
29312609 |
2017 |
|
Malignant tumor of colon
|
0.350 |
Biomarker
|
disease |
BEFREE |
However, its involvement in colon cancer and downstream molecular events is largely undefined; in particular, the mechanism by which Ascl2 regulates the plasticity of epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) programs in colon cancer cells remains unknown.
|
25371200 |
2014 |
|
Malignant tumor of colon
|
0.350 |
Biomarker
|
disease |
CTD_human |
Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
15059925 |
2004 |
|
Colonic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
15059925 |
2004 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ASCL2 was identified as a causative gene involved in therapeutic resistance against anticancer treatments in CRC.
|
30706227 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
WiNTRLINC1 is a long non-coding RNA (lncRNA) that positively regulates the Wnt pathway via achaete-scute complex homolog 2 (ASCL2) in colorectal cancer.
|
31549316 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human achaete scute homolog 2 (HASH2) and its murine ortholog MASH2 are potential targets for colorectal cancer immunotherapy.
|
30682058 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population.
|
30718926 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the involvement of ASCL2, a Wnt target gene and key determinant of intestinal stem cell state, in L1-mediated CRC progression.
|
29551399 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicated that Ascl2 autoregulation formed a transcriptional switch that was enhanced by Wnt signaling in the CD133<sup>+</sup>CD44<sup>+</sup> CRC population, thus conferring their self-renewal.
|
29886802 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our study demonstrated that Ascl2, a fate decider of CRC progenitor cells can be activated by the Hippo signaling pathway in CRC progenitor cells, and ensured their self-renewability.
|
29312609 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that hypoxia inducible factor-1α (HIF-1α) mRNA levels were positively correlated with Ascl2 mRNA levels and inversely correlated with miR-200b in CRC samples.
|
28899657 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the Ascl2/CDX2 axis may serve as a potential therapeutic target in colorectal cancer.
|
26307678 |
2015 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer.
|
25277775 |
2015 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Specifically, ASCL2 enhanced the invasion and metastasis of CRC cells in vitro and expression of ASCL2 correlated with distant metastasis, tumour size and poor overall survival in CRC patients.
|
25866254 |
2015 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that 74-85% of colorectal cancers express a Lgr5/Ascl2 associated signature and support the hypothesis that they derive from Lgr5(+)/Ascl2(+) crypt stem cells, not Bmi1(+) stem cells.
|
22637696 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain.
|
20479215 |
2010 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Self-antigen MASH2 combined with the AS15 immunostimulant induces tumor protection in colorectal cancer mouse models.
|
30682058 |
2019 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
ASCL2 protein expression was detected in 32 cases of gastric metastasis and its relevant primary tumors using western blotting and immunohistochemistry.
|
30106147 |
2018 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In human CRC tissue, ASCL2 was detected in the nuclei of cells at invasive areas of the tumor that also expressed L1.
|
29551399 |
2018 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Multivariable Cox-regression analysis showed that elevated expression of ASCL2 was an independent and unfavorable indicator of tumor relapse in breast cancer patients.
|
28469967 |
2017 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer.
|
25277775 |
2015 |